Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Nektar gains 5% as jury awards $90M plus interest in Lilly trial seekingalpha.com